Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancers|February 9, 2021
The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant ChemotherapyToshiaki Iwase, Aaroh Parikh, Seyedeh S Dibaj, et al.
BMC Cancer|May 20, 2020
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBCToshiaki Iwase, Kenichi Harano, Hiroko Masuda, et al.
Cancer Medicine|December 19, 2019
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancerNaoto T Ueno, Rie K Tahara, Takeo Fujii, et al.
Journal of Cancer|October 23, 2024
Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapyToshiaki Iwase, Aaroh Parikh, Dong Wenli, et al.
Breast Cancer Research and Treatment|August 2, 2025
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective studyToshiaki Iwase, Nithya Sridhar, Megumi Kai, et al.
Breast Cancer Research and Treatment|December 28, 2023
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancerFaina Nakhlis, Samuel M Niman, Naoto T Ueno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
British Journal of Cancer|May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatmentBora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Science Advances|December 16, 2022
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancerXiaoping Wang, Takashi Semba, Ganiraju C Manyam, et al.
Pageof 4